INT177840

Context Info Confidence 0.41 First Reported 2004 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 3 Total Number 6 Disease Relevance 3.37 Pain Relevance 1.27

peptidase activity (PLAU) signal transduction (PLAU) extracellular space (PLAU) extracellular region (PLAU) plasma membrane (PLAU)

Anatomy Link Frequency HeLa 1 superior 1 FaDu 1 PLAU (Homo sapiens)

Pain Link Frequency Relevance Heat aspirin 10 94.92 cINOD 12 78.44 Inflammation 14 77.84 COX-2 inhibitor 24 69.72 COX2 6 58.96 adenocard 2 17.04 cytokine 4 5.00 metalloproteinase 2 5.00 Glutamate 2 5.00

Disease Link Frequency Relevance Heat Carcinoma 48 99.76 Cancer 266 97.88 Colon Cancer 80 90.72 Metastasis 54 79.28 INFLAMMATION 18 77.84 Residual Neoplasm 8 67.12 Malignant Neoplastic Disease 12 13.76 Apoptosis 22 5.00 Skin Cancer 16 5.00 Reprotox - General 1 12 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

In invasive human colonocytes butyrate inhibited urokinase plasminogen activator (uPA) activity, and downregulated PCNA and TP53 levels after exposure for 12–18 hours [77].

Negative_regulation (inhibited) of uPA

1) Confidence 0.41 Published 2004 Journal J Carcinog Section Body Doc Link PMC421747 Disease Relevance 0.38 Pain Relevance 0.60

In invasive human colonocytes butyrate inhibited urokinase plasminogen activator (uPA) activity, and downregulated PCNA and TP53 levels after exposure for 12–18 hours [77].

Negative_regulation (inhibited) of urokinase plasminogen activator

2) Confidence 0.41 Published 2004 Journal J Carcinog Section Body Doc Link PMC421747 Disease Relevance 0.38 Pain Relevance 0.60

Hence, the neo-angiogenic potential of FaDu and HeLa cells was strongly reduced upon inhibition of COX-2, MMPs, and the uPA-system.

Negative_regulation (inhibition) of uPA in HeLa

3) Confidence 0.18 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2841144 Disease Relevance 0.77 Pain Relevance 0

Triple inhibition of uPA, MMPs, and COX-2 decreases the invasive capacity of tumour cells

Negative_regulation (inhibition) of uPA associated with cancer

4) Confidence 0.15 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2841144 Disease Relevance 0.37 Pain Relevance 0.03

Combinatorial treatment of carcinoma cells with inhibitors of the uPA system (WX-UK1), MMPs (Galardin), and COX-2 (Celecoxib) is superior to the single treatment with WK-UK1 alone.

Negative_regulation (inhibitors) of uPA in superior associated with carcinoma

5) Confidence 0.15 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2841144 Disease Relevance 0.71 Pain Relevance 0.03

Hence, the neo-angiogenic potential of FaDu and HeLa cells was strongly reduced upon inhibition of COX-2, MMPs, and the uPA-system.

Negative_regulation (inhibition) of uPA in FaDu

6) Confidence 0.06 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2841144 Disease Relevance 0.77 Pain Relevance 0

General Comments

This test has worked.